Biotech Startups

NeuroQore develops neuromodulation treatments for neurobehavioral conditions, focusing on treatment-resistant major depressive disorder and suicidality. It works with universities and research clinics to investigate new interventions as alternatives to existing treatments like rTMS and ECT.

1 investor

NeuroSky provides biofeedback and biometric assessment solutions that help companies optimize hiring decisions, identify employee training needs, and improve workforce productivity through data-driven insights on cognitive performance and employee capabilities.

1 investor

NeuroTherapia is a clinical-stage biotech company developing novel treatments for neuroinflammatory disorders, including Alzheimer's disease, neuropathic pain, multiple sclerosis, and ALS. Its lead candidate, NTRX-07, is a CB2 receptor agonist designed to reduce neuroinflammation and promote neuronal survival.

1 investor

Neuroute is an AI-powered platform that accelerates clinical trial execution through patient recruitment, trial monitoring, and predictive analytics. It serves pharmaceutical companies and clinical research organizations conducting clinical trials.

1 investor

NeuroXess is a life-science company founded in 2021 that develops implantable flexible brain-computer interface systems, with in-house development across hardware, algorithms, and software. Its technology aims to help patients with conditions such as ALS, high-level paraplegia, and stroke restore movement and speech functions.

1 investor

Neutrolis is a clinical-stage biotech developing first-in-class therapies that degrade neutrophil extracellular traps (NETs) to address the root cause of autoimmune and inflammatory diseases such as lupus and rheumatoid arthritis. Its approach targets the process of NETosis to treat these disorders without relying on immunosuppression.

1 investor

NEUVOGEN is a biotechnology company developing therapeutic cancer vaccines, using a whole tumor cell vaccine platform aimed at addressing the complexity of solid tumors.

1 investor

New Dawn Bio produces wood grown through cell culture rather than harvested from trees. The company applies biotechnology to create cultured wood materials.

1 investor

1 investor

New Frontier Bio is a biotechnology company with a cross-functional management team experienced in start-ups, science, strategy, and M&A across healthcare, biotechnology, and cosmetics.

1 investor

New Life Minds develops technology combining healthcare, life sciences, synthetic biology, and machine learning, with a stated focus on advancing brain evolution.

1 investor

New West Genetics breeds non-GMO industrial hemp seed varieties, using traditional breeding and genomics to create regionally adapted, high-yield genetics for grain, fiber, feed, and fuel applications. Its products, including the ABOUND multi-purpose varieties and AMPLIFY hybrid trait, are sold to hemp growers and agricultural producers, primarily in the United States.

1 investor

An independent nonprofit academic research institution that convenes talent from academic, research, and medical institutions to advance collaborative genomic research and accelerate discoveries in the genetic basis of disease for clinical diagnosis and treatment.

1 investor

New Zealand Clinical Research (NZCR) is a clinical trials and medical research organization that conducts early-phase and later-phase clinical research for pharmaceutical, biotech, and contract research organizations. With over 35 years of experience and multiple facilities across New Zealand, the organization specializes in testing new medicines and treatments across various therapeutic areas including gene therapy, hepatology, and vaccines.

1 investor

New Era develops sustainable colour solutions using biotechnology. The company serves industries requiring clean and clear colour products.

1 investor

Newlight uses ocean microorganisms to convert air and methane-based greenhouse gas into PHB, a biodegradable material it calls AirCarbon that can be molded into shapes, fibers, and sheets. The company applies this technology to produce materials aimed at addressing plastic pollution and climate change.

1 investor

NewMoo produces dairy proteins grown inside plants using molecular science, offering animal-free alternatives to traditional milk proteins for food brands. The product is designed to reduce land use, water consumption, and greenhouse gas emissions compared to conventional dairy.

1 investor

Newomics develops the UniESI system, a multiomics front-end platform using its M3 emitter and MEA chip "multispray" technologies for microflow and nanoflow LC-MS. The system serves as a dual nano/micro ion source for mass spectrometers, targeting applications in native MS, proteomics, metabolomics, and single-cell omics.

1 investor

Wageningen Future Food Institute (WFFI) develops functional proteins such as lactoferrin and the sweet protein thaumatin through precision fermentation, operating its own technology platform and partner network for R&D through pilot-scale production. Based in Wageningen, it runs a research hub supporting precision-fermentation startups and works to build Sino-Dutch industry and academic partnerships.

1 investor

New Wave Biotech builds an AI-powered platform that optimizes downstream bioprocessing with integrated techno-economic and sustainability analysis, serving R&D and operations teams in food, pharmaceutical, and industrial biotech companies.

1 investor

1 investor

Nexgenia develops proprietary stimuli-responsive polymer-based reagents for molecular and cellular selection, diagnostics, and immunoassays. The company's technology enables faster and more efficient separation and analysis of cells and molecules through reversible phase transitions triggered by temperature, pH, or salt changes.

1 investor

Nexotx is a drug discovery company that identifies and develops medicines targeting previously undrugged biological pathways using chemical biology approaches. The company serves patients by translating novel scientific targets into therapeutic candidates.

1 investor

NextCell Pharma is a Swedish biotech company developing stem cell therapies (advanced therapy medicinal products) focused primarily on autoimmune and inflammatory diseases, with its lead candidate ProTrans targeting type 1 diabetes. The company operates three business areas — Cellaviva, ProTrans, and QVance — and runs Cellaviva, described as Scandinavia's largest stem cell bank.

1 investor